News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
275,134 Results
Type
Article (14310)
Company Profile (105)
Press Release (260711)
Multimedia
Podcasts (65)
Webinars (13)
Section
Business (88556)
Career Advice (465)
Deals (15447)
Drug Delivery (73)
Drug Development (36857)
Employer Resources (50)
FDA (6410)
Job Trends (6248)
News (151243)
Policy (14192)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (449)
Accelerated approval (13)
Adcomms (8)
Allergies (67)
Alliances (23412)
ALS (60)
Alzheimer's disease (481)
Antibody-drug conjugate (ADC) (99)
Approvals (6602)
Artificial intelligence (201)
Autoimmune disease (40)
Automation (12)
Bankruptcy (150)
Best Places to Work (4380)
BIOSECURE Act (9)
Biosimilars (118)
Biotechnology (40)
Bladder cancer (38)
Brain cancer (30)
Breast cancer (172)
Cancer (1331)
Cardiovascular disease (151)
Career advice (418)
Career pathing (13)
CAR-T (49)
CDC (6)
Cell therapy (150)
Cervical cancer (9)
Clinical research (32148)
Collaboration (731)
Compensation (326)
Complete response letters (33)
COVID-19 (783)
CRISPR (43)
C-suite (433)
Cystic fibrosis (58)
Data (1849)
Denatured (18)
Depression (45)
Diabetes (133)
Diagnostics (1420)
Digital health (9)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (113)
Drug pricing (114)
Drug shortages (12)
Duchenne muscular dystrophy (81)
Earnings (33634)
Editorial (20)
Employer branding (4)
Employer resources (45)
Events (39212)
Executive appointments (531)
FDA (7516)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (435)
Gene editing (70)
Generative AI (18)
Gene therapy (168)
GLP-1 (441)
Government (1408)
Grass and pollen (4)
Guidances (166)
Healthcare (3638)
HIV (11)
Huntington's disease (9)
IgA nephropathy (37)
Immunology and inflammation (68)
Immuno-oncology (14)
Indications (53)
Infectious disease (847)
Inflammatory bowel disease (73)
Inflation Reduction Act (7)
Influenza (25)
Intellectual property (115)
Interviews (60)
IPO (5935)
IRA (33)
Job creations (2062)
Job search strategy (374)
JPM (28)
Kidney cancer (9)
Labor market (28)
Layoffs (206)
Leadership (8)
Legal (3459)
Liver cancer (22)
Longevity (8)
Lung cancer (186)
Lymphoma (124)
Machine learning (13)
Management (17)
Manufacturing (416)
MASH (67)
Medical device (1366)
Medtech (1373)
Mergers & acquisitions (9936)
Metabolic disorders (442)
Multiple sclerosis (46)
NASH (14)
Neurodegenerative disease (83)
Neuropsychiatric disorders (37)
Neuroscience (896)
Neurotech (1)
NextGen: Class of 2026 (1588)
Non-profit (608)
Now hiring (17)
Obesity (228)
Opinion (141)
Ovarian cancer (39)
Pain (109)
Pancreatic cancer (51)
Parkinson's disease (82)
Partnered (11)
Patents (224)
Patient recruitment (117)
Peanut (12)
People (29787)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase 1 (8335)
Phase 2 (13587)
Phase 3 (12263)
Pipeline (1923)
Policy (135)
Postmarket research (1403)
Preclinical (3356)
Press Release (25)
Prostate cancer (84)
Psychedelics (16)
Radiopharmaceuticals (137)
Rare diseases (352)
Real estate (2670)
Recruiting (18)
Regulatory (11010)
Reports (15)
Research institute (582)
Resumes & cover letters (55)
Rett syndrome (5)
RNA editing (6)
RSV (20)
Schizophrenia (69)
Series A (80)
Series B (50)
Service/supplier (2)
Sickle cell disease (46)
Special edition (10)
Spinal muscular atrophy (81)
Sponsored (9)
Startups (1651)
State (2)
Stomach cancer (5)
Supply chain (49)
Tariffs (68)
The Weekly (45)
Vaccines (231)
Venture capital (32)
Weight loss (140)
Women's health (27)
Worklife (4)
Date
Last 7 days (180)
Last 30 days (709)
Last 365 days (10506)
2026 (957)
2025 (10824)
2024 (12625)
2023 (14332)
2022 (19636)
2021 (20145)
2020 (19093)
2019 (14948)
2018 (11777)
2017 (13950)
2016 (13172)
2015 (15518)
2014 (12525)
2013 (10662)
2012 (11450)
2011 (12020)
2010 (10984)
Location
Africa (319)
Alabama (20)
Alaska (1)
Arizona (77)
Arkansas (3)
Asia (20926)
Australia (2689)
California (3196)
Canada (1483)
China (551)
Colorado (143)
Connecticut (131)
Delaware (123)
Europe (41585)
Florida (601)
Georgia (65)
Hawaii (1)
Idaho (10)
Illinois (349)
India (44)
Indiana (240)
Iowa (2)
Japan (247)
Kansas (77)
Kentucky (20)
Louisiana (4)
Maine (2)
Maryland (423)
Massachusetts (2633)
Michigan (46)
Minnesota (165)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (18)
New Hampshire (8)
New Jersey (1397)
New Mexico (7)
New York (907)
North Carolina (619)
North Dakota (2)
Northern California (1457)
Ohio (80)
Oklahoma (5)
Oregon (18)
Pennsylvania (716)
Puerto Rico (12)
Rhode Island (17)
South America (509)
South Carolina (10)
Southern California (1395)
Tennessee (53)
Texas (457)
United States (12750)
Utah (60)
Virginia (160)
Washington D.C. (42)
Washington State (223)
West Virginia (1)
Wisconsin (39)
Wyoming (1)
275,134 Results for "nls pharmaceutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
NLS Pharmaceutics Announces Registered Direct Offering
NLS Pharmaceutics Ltd. announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,277,750 of its common shares at a purchase price of $0.24 per share in a registered direct offering.
June 28, 2024
·
6 min read
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
NLS Pharmaceutics Ltd. today announced that Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics will attend the BIO-EUROPE Springtime Partnering Event taking place March 18-20, 2024.
March 14, 2024
·
1 min read
Drug Development
NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson’s Disease Treatments
NLS Pharmaceutics Ltd. today announced preclinical results from multiple in vitro studies targeting alpha-synuclein specifically the A53T mutation, that demonstrate the compounds’ potential to advance the treatment of Parkinson’s Disease (PD).
June 27, 2024
·
6 min read
NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced the publication of the latest patent application (PCT/WO2024115797) by Aexon Labs with the World Intellectual Property Organization (WIPO).
June 11, 2024
·
7 min read
Deals
Nasdaq Panel Grants NLS Pharmaceutics’ Request for Extension to Comply with Continued Listing Requirements
NLS Pharmaceutics Ltd. announced today that it received notice from the Nasdaq Hearings Panel of The Nasdaq Stock Market that it has granted the Company an extension to regain compliance with the continued listing requirements for The Nasdaq Capital Market, as discussed more fully below.
June 25, 2024
·
4 min read
Press Releases
Leyden Labs Secures €30 million from European Innovation Council Fund and Invest-NL to Advance Nasal Spray Against Respiratory Viruses
October 2, 2025
·
5 min read
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance
NLS Pharmaceutics Ltd. announced that it has been notified by the Listing Qualifications Department of the Nasdaq Stock Market LLC that the Company’s plan to regain compliance submitted on February 23, 2024 has been approved.
March 11, 2024
·
4 min read
NLS Pharmaceutics Announces Company Update on Strategic Partnerships
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (“NLS” or the “Company”) today announced plans to issue an important update on discussion the company is having regarding strategic partnerships, including Timeline for the company’s Phase 3 program in narcolepsy.
October 12, 2023
·
1 min read
Press Releases
NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement
April 1, 2025
·
10 min read
Business
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (“NLS”), a leading Swiss biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, announced today a groundbreaking exclusive worldwide license agreement (the “License Agreement”) with Aexon Labs, Inc., a U.S.-based biotech firm (“Aexon”).
March 20, 2024
·
9 min read
1 of 27,514
Next
